Nuclear receptor subfamily 1 group H member 4 (NR1H4)
Nuclear receptor subfamily 1 group H member 4, also known as farnesoid X receptor (FXR), is a ligand-activated nuclear receptor that functions as a key regulator of bile acid homeostasis and broader metabolic signaling.
Nuclear receptor subfamily 1 group H member 4, also known as farnesoid X receptor (FXR), is a ligand-activated nuclear receptor that functions as a key regulator of bile acid homeostasis and broader metabolic signaling. It is highly expressed in the liver and intestine, where it senses bile acids and coordinates transcriptional programs that influence bile acid synthesis, transport, lipid metabolism, and inflammatory responses. Because of this central role, FXR has become an important biomedical target in metabolic dysfunction–associated steatotic liver disease and Metabolic dysfunction associated steatohepatitis, as well as in related disorders involving obesity and dyslipidemia.
In therapeutic research, FXR is commonly studied as part of enterohepatic signaling axes that connect the gut microbiota, bile acid composition, and hepatic metabolism. Modulation of FXR signaling can alter downstream pathways such as FXR/CYP7A1/CYP8B1, FXR/SHP/SREBP-1c, and alternative bile acid synthesis routes involving CYP7B1 and CYP27A1. Recent studies have also examined FXR in combination with other targets, including HSD17B13 and the GLP-1 receptor, reflecting its role as a node in multi-target strategies for metabolic disease.
Where the papers sit
9 papers from the last 6 months study Nuclear receptor subfamily 1 group H member 4 (NR1H4) directly · updated from PubMed 5 Nov 2026
Study type 0 clinical trials · 5 preclinical · 4 unclassified
Themes 3 themes
-
FXR Therapies for MASLD
FXR modulation is being paired with dietary, botanical, and combination approaches to reduce steatosis in MASLD. Intestinal FXR loss can uncouple protection from lipid accumulation from control of inflammation and fibrosis, highlighting tissue-specific effects. Hepatic FXR mRNA delivery with lipid nanoparticles improves the response to a low-dose FXR agonist. Bile acid remodeling and coordinated control of NF-κB and SLC22A7 recur as therapeutic goals.
4 papers · 44.4%
-
FXR in Liver Inflammation
FXR-centered control of bile acids and inflammation links MASH, steatohepatitis, and liver-tumor biology. Interventions target gut dysbiosis, intestinal barrier function, and the SIRT1-dependent NLRP3 pathway, with IL-1β and inflammatory signaling as recurring endpoints. Bile acid retention is also associated with impaired antigen presentation and tumor suppression in MASH-associated HCC. The work remains preclinical and spans both liver disease treatment and FXR-linked drug metabolism in colitis.
4 papers · 44.4%
-
FXR and Neuroinflammation
FXR signaling is being explored as a way to suppress microglial inflammation and depression-like behavior. Methyl dichloroasterrate increases FXR activity in lipopolysaccharide-challenged mice while reducing NLRP3 activation and neuroinflammatory responses. Behavioral outcomes, including sucrose preference, connect the molecular findings to depressive phenotypes. Evidence remains limited to preclinical models, leaving the relevant brain mechanisms and therapeutic applicability unresolved.
1 papers · 11.1%
Papers
The 9 papers from the last 6 months that study Nuclear receptor subfamily 1 group H member 4 (NR1H4) directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
FXR Therapies for MASLD (4)
- Hepatic delivery of FXR mRNA via lipid nanoparticles enhances the efficacy of a low-dose FXR agonist in the treatment of MASLD. Nanomedicine : nanotechnology, biology, and medicine · 3 Oct 2026 PMID 42829150
- Babaodan Ameliorates Metabolic Dysfunction-Associated Steatotic Liver Disease with Co-Modulation of FXR, NF-κB, and SLC22A7 in Bile Acid Metabolism. Journal of ethnopharmacology · 19 Jul 2026 PMID 42472598
- Intestinal FXR deficiency uncouples steatosis protection from liver inflammation and fibrosis in MASH-diet fed mice. Scientific reports · 10 Jul 2026 PMID 42431962
- The hawthorn (Crataegus pinnatifida) procyanidin extract attenuates nonalcoholic fatty liver disease in mice via remodeling the bile acid profile driven by gut microbiota and regulating the FXR pathway. Food & function · 16 Jun 2026 PMID 42300918
FXR in Liver Inflammation (4)
- PMID 42105596
- Tetramethylpyrazine ameliorates metabolic dysfunction-associated steatohepatitis by modulating gut microbiota dysbiosis and restoring intestinal barrier integrity. British journal of pharmacology · 11 Sept 2026 PMID 42723361
- CD38 Inhibition Enhances FXR Signaling in Male Rats With Diabetic Steatohepatitis Through SIRT1-Dependent Suppression of NLRP3. FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 4 Aug 2026 PMID 42550583
- Bile acid retention impairs tumoral antigen presentation and intrinsic tumor suppression in MASH-HCC. Cancer letters · 22 May 2026 PMID 42173274
FXR and Neuroinflammation (1)
- Methyl dichloroasterrate alleviates lipopolysaccharide-induced neuroinflammation and depression-like behaviors in mice by upregulating FXR expression. International immunopharmacology · 12 Jun 2026 PMID 42284761
By study type
Preclinical: animal, cell and lab studies (5)
- Design, Synthesis, and Biological Evaluation of Pentacyclic Triterpene Derivatives as Intestinal FXR Antagonists for Type 2 Diabetes. Journal of medicinal chemistry · 12 Nov 2026 PMID 43018576
- CD38 Inhibition Enhances FXR Signaling in Male Rats With Diabetic Steatohepatitis Through SIRT1-Dependent Suppression of NLRP3. FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 4 Aug 2026 PMID 42550583
- The hawthorn (Crataegus pinnatifida) procyanidin extract attenuates nonalcoholic fatty liver disease in mice via remodeling the bile acid profile driven by gut microbiota and regulating the FXR pathway. Food & function · 16 Jun 2026 PMID 42300918
- Methyl dichloroasterrate alleviates lipopolysaccharide-induced neuroinflammation and depression-like behaviors in mice by upregulating FXR expression. International immunopharmacology · 12 Jun 2026 PMID 42284761
- Bile acid retention impairs tumoral antigen presentation and intrinsic tumor suppression in MASH-HCC. Cancer letters · 22 May 2026 PMID 42173274
Unclassified: not yet indexed with MeSH (4)
- Hepatic delivery of FXR mRNA via lipid nanoparticles enhances the efficacy of a low-dose FXR agonist in the treatment of MASLD. Nanomedicine : nanotechnology, biology, and medicine · 3 Oct 2026 PMID 42829150
- Tetramethylpyrazine ameliorates metabolic dysfunction-associated steatohepatitis by modulating gut microbiota dysbiosis and restoring intestinal barrier integrity. British journal of pharmacology · 11 Sept 2026 PMID 42723361
- Babaodan Ameliorates Metabolic Dysfunction-Associated Steatotic Liver Disease with Co-Modulation of FXR, NF-κB, and SLC22A7 in Bile Acid Metabolism. Journal of ethnopharmacology · 19 Jul 2026 PMID 42472598
- Intestinal FXR deficiency uncouples steatosis protection from liver inflammation and fibrosis in MASH-diet fed mice. Scientific reports · 10 Jul 2026 PMID 42431962
Written from 9 PubMed abstracts, each one listed by PMID above. Published: 2026-07-19. Last written: 2026-09-13 by GPT. Drafted by language models from published abstracts; not medical advice.